Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis
- PMID: 24469043
- PMCID: PMC4112178
- DOI: 10.1038/onc.2013.563
Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis
Abstract
The membrane-anchored serine protease, matriptase, is consistently dysregulated in a range of human carcinomas, and high matriptase activity correlates with poor prognosis. Furthermore, matriptase is unique among tumor-associated proteases in that epithelial stem cell expression of the protease suffices to induce malignant transformation. Here, we use genetic epistasis analysis to identify proteinase-activated receptor (PAR)-2-dependent inflammatory signaling as an essential component of matriptase-mediated oncogenesis. In cell-based assays, matriptase was a potent activator of PAR-2, and PAR-2 activation by matriptase caused robust induction of nuclear factor (NF)κB through Gαi. Importantly, genetic elimination of PAR-2 from mice completely prevented matriptase-induced pre-malignant progression, including inflammatory cytokine production, inflammatory cell recruitment, epidermal hyperplasia and dermal fibrosis. Selective ablation of PAR-2 from bone marrow-derived cells did not prevent matriptase-driven pre-malignant progression, indicating that matriptase activates keratinocyte stem cell PAR-2 to elicit its pro-inflammatory and pro-tumorigenic effects. When combined with previous studies, our data suggest that dual induction of PAR-2-NFκB inflammatory signaling and PI3K-Akt-mTor survival/proliferative signaling underlies the transforming potential of matriptase and may contribute to pro-tumorigenic signaling in human epithelial carcinogenesis.
Conflict of interest statement
Authors have declared that no competing interests exist.
Figures






Similar articles
-
Protease-activated Receptor-2 (PAR-2)-mediated Nf-κB Activation Suppresses Inflammation-associated Tumor Suppressor MicroRNAs in Oral Squamous Cell Carcinoma.J Biol Chem. 2016 Mar 25;291(13):6936-45. doi: 10.1074/jbc.M115.692640. Epub 2016 Feb 2. J Biol Chem. 2016. PMID: 26839311 Free PMC article.
-
Role of matriptase and proteinase-activated receptor-2 in nonmelanoma skin cancer.J Invest Dermatol. 2009 Jul;129(7):1816-23. doi: 10.1038/jid.2008.449. Epub 2009 Feb 26. J Invest Dermatol. 2009. PMID: 19242518
-
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.Genes Dev. 2005 Aug 15;19(16):1934-50. doi: 10.1101/gad.1300705. Genes Dev. 2005. PMID: 16103220 Free PMC article.
-
Novel initiation genes in squamous cell carcinomagenesis: a role for substrate-specific ubiquitylation in the control of cell survival.Mol Carcinog. 2007 Aug;46(8):585-90. doi: 10.1002/mc.20344. Mol Carcinog. 2007. PMID: 17626251 Review.
-
Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis.Front Biosci. 2007 Sep 1;12:5060-70. doi: 10.2741/2448. Front Biosci. 2007. PMID: 17569630 Review.
Cited by
-
Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.Antiviral Res. 2015 Nov;123:78-85. doi: 10.1016/j.antiviral.2015.09.002. Epub 2015 Sep 4. Antiviral Res. 2015. PMID: 26343910 Free PMC article.
-
Matriptase zymogen supports epithelial development, homeostasis and regeneration.BMC Biol. 2017 Jun 1;15(1):46. doi: 10.1186/s12915-017-0384-4. BMC Biol. 2017. PMID: 28571576 Free PMC article.
-
Coagulation signaling to epithelia.Blood. 2016 Jun 23;127(25):3114-6. doi: 10.1182/blood-2016-05-715052. Blood. 2016. PMID: 27340252 Free PMC article.
-
Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis.Res Rep Urol. 2019 Apr 11;11:97-104. doi: 10.2147/RRU.S199512. eCollection 2019. Res Rep Urol. 2019. PMID: 31114765 Free PMC article.
-
The role of type II transmembrane serine protease-mediated signaling in cancer.FEBS J. 2017 May;284(10):1421-1436. doi: 10.1111/febs.13971. Epub 2016 Dec 24. FEBS J. 2017. PMID: 27870503 Free PMC article. Review.
References
-
- Lopez-Otin C, Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer. 2010;10(4):278–292. - PubMed
-
- Benaud C, Oberst M, Hobson JP, Spiegel S, Dickson RB, Lin CY. Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem. 2002;277(12):10539–10546. - PubMed
-
- Hoang CD, D'Cunha J, Kratzke MG, Casmey CE, Frizelle SP, Maddaus MA, et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest. 2004;125(5):1843–1852. - PubMed
-
- Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF, Lin YF. Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol. 2006;14(1):65–72. - PubMed
-
- Jin JS, Hsieh DS, Loh SH, Chen A, Yao CW, Yen CY. Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod Pathol. 2006;19(3):447–452. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous